23 de octubre de 2019
30 de agosto de 2009

New Large-Scale, Global Study Provides Additional Information About an Intensified Dose-Regimen of PLAVIX(R) in Acute Co

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the research, development and commercialization of products. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among other risks, there can be no guarantee that the clinical trials described in this release will support a regulatory filing. Forward-looking statements in the press release should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb's business, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2008, its Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Ingrid Gorg-Armbrecht, Media, +33-153-774-625, Mobile: +33-686-056-688, or ingrid.goerg-armbrecht@sanofi-aventis.com, Sebastien Martel, Investors, +33-153-774-545, or ir@sanofi-aventis.com, both of sanofi-aventis; Laura Hortas, Media, +1-609-240-7025, or laura.hortas@bms.com , John Elicker, Investors, +1-609-252-4611, or john.elicker@bms.com, both of Bristol-Myers Squibb